Follistatin-344: The Myostatin-Blocking Peptide at the Muscle-Growth Frontier

Follistatin-344 is the research-peptide version of follistatin, a natural human protein whose job is to switch off the body's own brakes on muscle growth. Those brakes are myostatin and activin, and because follistatin binds and neutralizes both of them, it sits at one of the most exciting and most hyped frontiers in muscle science, which is why it surfaces on discussions of the best peptides for muscle growth. The catch, the one this whole guide keeps coming back to, is that the jaw-dropping muscle results come almost entirely from animals and from gene therapy, not from the vial of "follistatin-344" you can buy online.

If you have seen "double-muscled" cattle, the myostatin-knockout "mighty mouse," or headlines about a "follistatin gene therapy" that grows muscle, this page is the high-level map of the whole compound. We cover what follistatin-344 actually is, how myostatin blockade works, what the real evidence does and does not show, the doses people report, the honest safety and legal picture, and how it differs from antibody-style myostatin inhibitors. Each section is a clear overview; the deep-dive topics point to dedicated guides so this page stays a clean hub.

Key Takeaways

• Follistatin-344 (FS344) is a recombinant form of follistatin, an autocrine glycoprotein encoded by the FST gene that binds and inhibits myostatin, activin, and related TGF-β family proteins (UniProtKB, "Follistatin (P19883)", 2026; Wikipedia, "Follistatin", retrieved 2026-06-15).
• It grows muscle by removing a brake, not adding a gas pedal. Myostatin (GDF-8) normally limits muscle size; follistatin sequesters myostatin and activin, so its effect exceeds blocking myostatin alone (Am J Physiol Endocrinol Metab, 2009, retrieved 2026-06-15).
• The muscle evidence is animal- and gene-therapy-derived, not from the injected peptide. A single AAV gene delivery of follistatin enhanced muscle mass and strength in mice for over two years (PNAS, Haidet et al., 2008, retrieved 2026-06-15); small human studies used gene therapy, not injections.
• The injected "follistatin-344 peptide" has essentially no published human efficacy data, and a 2019 black-market analysis found only 9 of 17 products actually contained follistatin (Drug Testing and Analysis, 2019, retrieved 2026-06-15).
• Reported community doses cluster around 100 mcg/day by subcutaneous injection in short 10-30 day cycles. These are community figures, not validated dosing; no human dose-finding study exists.
• It is not FDA-approved and is banned in sport. Myostatin-binding proteins like follistatin fall under WADA's S4 (Hormone and Metabolic Modulators, section 4.3), and follistatin gene therapy falls under M3 (Gene and Cell Doping) (WADA Prohibited List, 2026, retrieved 2026-06-15).

What is Follistatin-344?

Follistatin-344 is a recombinant version of follistatin, a natural human protein that blocks the muscle-limiting signals myostatin and activin. The "344" refers to the FS344 form, a 344-amino-acid follistatin construct, which is the version most research-peptide vendors sell. It is studied for muscle growth, muscle-wasting diseases, and metabolic effects.

Follistatin itself is not a short "peptide" in the way BPC-157 is; it is an autocrine glycoprotein, a fairly large sugar-coated protein expressed in nearly every tissue, encoded by the FST gene (UniProt P19883). Its defining trick is that it acts as a high-affinity trap for several members of the TGF-β protein family, including myostatin (also called GDF-8) and activin, blocking them from reaching their receptors (UniProtKB, "Follistatin (P19883)", 2026, retrieved 2026-06-15). If injectable proteins and peptides are new to you, start with our what are peptides and how peptides work guides.

One nuance gets lost in marketing. Human follistatin has two main mature forms, FS-288 (which sticks to cell surfaces and binds activin most tightly) and FS-315 (the form that circulates in blood), and these arise from alternative splicing (Wikipedia, "Follistatin", retrieved 2026-06-15). "Follistatin-344" is best understood as the FS344 precursor/construct used to make recombinant follistatin (the same construct used in the gene-therapy work below), not a distinct hormone floating in your bloodstream. The single most important fact about it: like the research market it lives in, follistatin-344 is not approved by any drug regulator for any use.

Citation capsule. Follistatin-344 (FS344) is a recombinant form of follistatin, an autocrine glycoprotein encoded by the human FST gene (UniProt P19883; Entrez 10468; chromosome 5q11.2). Follistatin binds and inhibits TGF-β-family ligands including myostatin (GDF-8), activin, and GDF11, preventing them from activating their type II receptors. The two main mature isoforms are cell-bound FS-288 and circulating FS-315; FS344 is the precursor construct. Source: UniProtKB P19883, 2026; Wikipedia, "Follistatin," 2026.

How does Follistatin-344 work?

Follistatin-344 grows muscle by removing a brake rather than pressing an accelerator: it traps and neutralizes myostatin and activin, the proteins that normally tell muscle to stop growing. With those signals blocked, muscle satellite cells proliferate and muscle fibers enlarge. This mechanism is well established in animals; it is the injected-peptide application in humans that lacks evidence.

In plain terms, your body has a built-in governor on muscle size. The main governor is myostatin, a protein in the TGF-β family; the more myostatin signaling there is, the more muscle growth is held back. Follistatin works upstream by physically binding myostatin (and its cousin activin) so they cannot dock onto their receptors. A 2009 study put a fine point on why follistatin is more powerful than blocking myostatin alone, finding that "follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin" (Am J Physiol Endocrinol Metab, "Follistatin induces muscle hypertrophy...", 2009, retrieved 2026-06-15).

Nature ran this experiment for us long before any lab did. Animals with broken myostatin genes are dramatically over-muscled: "double-muscled" cattle breeds such as the Belgian Blue carry myostatin-inactivating mutations (PNAS, "Double muscling in cattle due to mutations in the myostatin gene", 1997, retrieved 2026-06-15). In 2004, doctors even described a child with a natural myostatin loss-of-function mutation who showed "gross muscle hypertrophy" with unusually strong muscles (N Engl J Med, Schuelke et al., 2004, retrieved 2026-06-15). Follistatin essentially mimics that "myostatin off" state chemically rather than genetically.

Here is what each piece of the mechanism contributes, in simple terms:

• Myostatin (GDF-8) blockade: removes the primary brake on muscle size, the same brake disabled in double-muscled cattle and the 2004 hypertrophy case.
• Activin blockade: follistatin also traps activin, adding a second growth signal that pure myostatin inhibitors do not touch, which is why its effect is broader.
• Satellite-cell proliferation: with the brakes off, muscle stem cells multiply and feed new nuclei into growing fibers.

The receptor-level deep dive (how activin type II receptors signal, the full TGF-β family) is its own topic. We keep it at overview level here and link out to how peptides work for the foundations.

How strong is the evidence for Follistatin-344?

The evidence for follistatin growing muscle is genuinely strong, but it is almost all from animals and from gene therapy, not from the injected "follistatin-344 peptide," which has essentially no published human efficacy data. This is the single most important thing to understand: the impressive numbers and the product in the vial are not the same intervention.

The foundational result is a 2008 study in which a single, one-time gene delivery (using a viral vector) of follistatin-based myostatin inhibitors enhanced muscle mass and strength in both healthy and dystrophic mice, with effects lasting over two years (PNAS, Haidet et al., "Long-Term Enhancement of Skeletal Muscle Mass and Strength by Single Gene Administration of Myostatin Inhibitors", 2008, retrieved 2026-06-15). The muscle-growth effect has since been reproduced across species; in 2016, researchers reported that "the transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs" (Transgenic Research, 2016, retrieved 2026-06-15). So the biology is not in doubt.

Why the human evidence is about gene therapy, not injections

It helps to separate two very different things that both get called "follistatin." The human studies that exist used follistatin gene therapy, a one-time injection of a viral vector that makes the muscle produce follistatin itself for a long time, not repeated shots of the protein. In a 2015 Phase 1/2a trial in Becker muscular dystrophy, six patients received the follistatin gene-therapy vector, and most showed meaningful improvement on the six-minute walk test (Molecular Therapy, Mendell et al., 2015, retrieved 2026-06-15). A 2017 trial in sporadic inclusion body myositis reported treated patients walked roughly 56 meters per year farther while untreated patients lost ground (Molecular Therapy, Mendell et al., 2017, retrieved 2026-06-15). Both were run by the gene-therapy program at Nationwide Children's Hospital.

Even those results carry caveats. A published commentary disputed how much of the functional improvement could fairly be attributed to the follistatin gene therapy in the myositis trial, arguing the claims were not well supported (Molecular Therapy, "Unfounded Claims of Improved Functional Outcomes...", 2017, retrieved 2026-06-15). And crucially, none of this tells you what happens when you inject the follistatin-344 protein subcutaneously, which is what the research-peptide market actually sells. There are no published human dose-response or efficacy studies for the injected peptide, and native circulating follistatin is cleared from the bloodstream very quickly, which is exactly why scientists pursued the gene-therapy route (sustained internal production) instead of repeated protein injections.

Our take: The most common mistake we see is collapsing three different things, the mouse data, the gene-therapy trials, and the vial of injectable peptide, into one claim that "follistatin builds insane muscle." The mouse and gene-therapy data are real and exciting. They are not evidence that injecting the protein does the same thing in a healthy adult, and honest framing means keeping those lanes separate.

What is Follistatin-344 used for?

Follistatin-344 is studied mainly for muscle growth and for muscle-wasting diseases such as muscular dystrophy, with secondary interest in fat loss, fertility biology, and recovery. In the research-peptide community it is used off-label as a muscle-building compound, but none of these are FDA-approved uses, and the strongest data sit in animals and gene-therapy trials.

The headline interest is muscle. Because follistatin mimics the "myostatin off" state, it has been pursued as a potential treatment for diseases that waste muscle, which is why the human gene-therapy trials targeted Becker muscular dystrophy and inclusion body myositis (Molecular Therapy, 2015, retrieved 2026-06-15). Follistatin biology also reaches beyond muscle: follistatin was originally characterized for its role in suppressing follicle-stimulating hormone via activin in reproductive biology, and activin blockade is linked to metabolic and fat-related effects, which is where the "fat loss" and broader-benefit claims come from.

A quick overview of the areas follistatin is studied for, and where the evidence stands:

Because several of these are distinct future articles, we keep them brief here. The honest headline: follistatin is one of the most promising muscle-biology targets known, but that promise has been demonstrated through genes and animals, not through a vial of injectable peptide.

What doses of Follistatin-344 do people report using?

There is no validated dose for follistatin-344, but reported community protocols cluster around 100 mcg per day by subcutaneous injection, run in short cycles of roughly 10 to 30 days. These are figures people report online, not an established or recommended dose, and there is no human dose-finding study to anchor them.

The most commonly cited pattern in community write-ups is about 100 mcg daily (some report 100-200 mcg/day) for a 10-to-30-day cycle, often repeated only a couple of times per year with long breaks in between (Jay Campbell, "Follistatin 344 Peptide", 2025, retrieved 2026-06-15). We label all of this as community convention because it rests on anecdote, not pharmacology: no regulator has reviewed a dose, there is no published human dose-response data for the injected protein, and a 2019 forensic analysis found the products themselves are often not even what the label claims, with only 9 of 17 "follistatin 344" products containing actual follistatin (Drug Testing and Analysis, "Detection of black market follistatin 344", 2019, retrieved 2026-06-15).

The detailed reconstitution math, syringe-unit conversions, and cycle theory are a dedicated spoke. We cover only the high-level framing here and link out to our peptide dosing calculator and the general peptide injections guide.

For orientation only, here is how people commonly describe the reported approach (not a recommendation):

Our take: A number like "100 mcg a day" gets repeated until it sounds like a protocol. It is not. It is a community convention with no human dose-finding behind it, layered on top of a market where roughly half the products tested did not contain the labeled compound. That combination is exactly why we frame every figure here as reported, not recommended.

Is Follistatin-344 safe?

Because the injected follistatin-344 peptide has barely been studied in humans, its true safety profile is unknown; the gene-therapy trials reported it was generally well tolerated, but that does not transfer to self-injected research-market product. "Unknown" is the honest headline, not "safe."

In the controlled gene-therapy studies, the follistatin vector was reported as generally well tolerated with no drug-related serious adverse events at the doses used (Molecular Therapy, Mendell et al., 2015, retrieved 2026-06-15). But that was a sterile, manufactured, dose-controlled product given under medical supervision, which is a different world from a reconstituted vial bought online. The biggest practical risk with the research-market peptide is the product itself: the 2019 black-market analysis that found only about half of "follistatin 344" products contained follistatin also found other products were spiked with entirely different compounds such as MGF or GHRP-2 (Drug Testing and Analysis, 2019, retrieved 2026-06-15).

A hub-level overview of what is reported and what is theorized:

• Quality-related risks (the biggest concern): mislabeled potency, wrong compound entirely, impurities, or non-sterile product, because the market is unregulated.
• Commonly reported (mild, anecdotal): injection-site reactions; community reports are not a substitute for safety data.
• Theoretical, mechanism-based: broadly switching off TGF-β-family brakes (myostatin and activin) is not a free lunch; these proteins have roles beyond muscle, so long-horizon effects of strong, sustained blockade are simply unstudied in self-dosing humans.
• Unknown: true long-term safety of the injected protein in healthy adults, because that data does not exist.

This is the hub-level summary of what is currently known about Follistatin-344's safety, with the unregulated product market remaining the single biggest practical risk.

How does Follistatin-344 compare to other myostatin inhibitors?

Follistatin-344 and antibody-style myostatin inhibitors like trevogrumab both aim to grow or preserve muscle, but they work at different points: follistatin is a broad upstream trap that blocks myostatin and activin, while an antibody such as trevogrumab targets myostatin specifically. That breadth-versus-precision difference is the cleanest way to tell the category apart.

Trevogrumab (REGN1033) is a monoclonal antibody developed by Regeneron that selectively binds and neutralizes myostatin (GDF-8), and it has been studied in clinical trials for muscle preservation, including alongside GLP-1 weight-loss drugs (Wikipedia, "Trevogrumab", retrieved 2026-06-15). Because it is an antibody aimed at one target, it is precise: it lowers myostatin signaling and little else. Follistatin is the opposite design philosophy: it is a natural binding protein that sweeps up several TGF-β-family signals at once, including activin, so its muscle effect can be broader, but it is also less selective and follows the unapproved research-market path rather than a regulated drug-development path.

So at a high level: follistatin-344 is the broad, upstream, research-market option, and an antibody like trevogrumab is the narrow, target-specific, clinically-developed option. They share the same honest caveat for a self-experimenter, though, since neither is an approved muscle-building drug you can simply use. That contrast is deliberately brief here to avoid overlapping the dedicated comparison: see trevogrumab and the myostatin-antibody approach, and for a related growth-pathway peptide, IGF-1 LR3.

Is Follistatin-344 legal?

Follistatin-344 is not approved by any regulator, so there is no official safety determination, and the injectable peptide sold online is an unapproved "research chemical," not a legal medicine or supplement; it is also banned in sport. That status matters more than any single study.

On legality, follistatin-344 is not an FDA-approved drug and is not a lawful dietary ingredient; vendors sell it "for research use only, not for human consumption," which places it in the same unapproved research-chemical category as most peptides discussed in this space. There is no legitimate "get a prescription" route for the injectable peptide outside of a clinical trial. In sport, the picture is clear: myostatin-binding proteins such as follistatin are prohibited under the World Anti-Doping Agency's Prohibited List in class S4 (Hormone and Metabolic Modulators, section 4.3, agents that prevent activin receptor activation), and follistatin gene therapy falls under class M3 (Gene and Cell Doping) (WADA Prohibited List, 2026, retrieved 2026-06-15; Drug Testing and Analysis, 2019, retrieved 2026-06-15).

For the full legal picture and how to evaluate a vendor, see are peptides legal and how to vet peptide quality.

Our take: The single most common misunderstanding is assuming that because follistatin-344 is sold openly online, it must be a legitimate muscle drug. It is sold "for research use only," it is unapproved, it is banned in sport, and forensic testing shows the vials frequently do not contain what they claim. Easy to buy is not the same as legal, safe, or even authentic.

How do people obtain Follistatin-344?

Because follistatin-344 is unapproved, the main way people access it is by buying unapproved "research chemical" vials online, which is a legal, safety, and authenticity gray market; there is no legitimate prescription route for the injectable peptide. The gene-therapy version that produced the real human data is a separate, experimental medical procedure, not something sold in a vial.

The research-peptide market is where most online searches end up: vendors sell lyophilized follistatin-344 "for research use only," and buyers reconstitute and use it off-label. As the 2019 forensic analysis showed, that market carries an unusually high authenticity risk for this specific compound, on top of the usual risks of impurities and non-sterile product (Drug Testing and Analysis, 2019, retrieved 2026-06-15).

If you are researching that path despite the risks, the responsible groundwork is the same as for any research peptide:

1. Confirm the legal status for your country and situation, including sport and workplace rules. See are peptides legal.
2. Demand a certificate of analysis (COA) from independent third-party testing, and read it for identity and purity, which matters more here than almost anywhere given the authenticity data. See how to vet peptide quality.
3. Understand handling first. Reconstitution and cold storage of a fragile protein are not optional. See getting started with peptides and the peptide injections guide.
4. Talk to a qualified clinician who can weigh your specific health situation, interactions, and contraindications.

We are describing what people do, not endorsing it. Using an unapproved protein means accepting unknown risks with no regulatory safety net.

A realistic look at expectations

The "double your muscle" stories around follistatin come from genetically altered animals and from gene therapy, not from injecting the peptide, so realistic expectations for the research-market product should be modest and skeptical. Going in calibrated is part of using any of this information responsibly.

Two honest caveats sit on top of the hype. First, the dramatic results, double-muscled cattle, the two-year mouse gains, the walking-distance improvements, came from changing genes or from controlled gene therapy, not from a subcutaneous shot of protein with a very short half-life. Second, even the human gene-therapy results were small and partly disputed, and the injected peptide has no human efficacy data at all. For grounded before-and-after context and how to read transformation claims, see peptides before and after.

Frequently Asked Questions

The bottom line

Follistatin-344 is one of the most scientifically exciting compounds in the muscle world and one of the easiest to misread. The underlying biology is genuinely powerful: follistatin neutralizes both myostatin and activin, the body's brakes on muscle growth, and when that brake is removed, whether in double-muscled cattle, myostatin-knockout mice, gene-therapy-treated dogs and pigs, or a rare human mutation, muscle grows dramatically. That is the real reason follistatin earned its "muscle-growth frontier" reputation.

The other half of the story is discipline. The product sold online is the injected follistatin-344 peptide, and that specific intervention has essentially no human efficacy data, a very short half-life, an unregulated market where roughly half of tested products were not what they claimed, no FDA approval, and a ban in sport. The honest label is investigational, and the gap between "remarkable in genes and animals" and "proven in a vial" is wide. From here, the natural next reads are how to vet peptide quality, are peptides legal, and getting started with peptides.

Sources

• UniProtKB. "Follistatin (FST), P19883." 2026 release. Retrieved 2026-06-15. https://www.uniprot.org/uniprotkb/P19883/entry
• Wikipedia. "Follistatin." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Follistatin
• Wikipedia. "Trevogrumab." Retrieved 2026-06-15. https://en.wikipedia.org/wiki/Trevogrumab
• Gilson, H., et al. "Follistatin induces muscle hypertrophy through satellite cell proliferation and inhibition of both myostatin and activin." American Journal of Physiology - Endocrinology and Metabolism, 2009. Retrieved 2026-06-15. https://journals.physiology.org/doi/full/10.1152/ajpendo.00193.2009
• Kambadur, R., et al. "Double muscling in cattle due to mutations in the myostatin gene." PNAS, 1997. Retrieved 2026-06-15. https://www.pnas.org/doi/10.1073/pnas.94.23.12457
• Schuelke, M., et al. "Myostatin Mutation Associated with Gross Muscle Hypertrophy in a Child." New England Journal of Medicine, 2004. Retrieved 2026-06-15. https://www.nejm.org/doi/full/10.1056/NEJMoa040933
• Haidet, A.M., et al. "Long-Term Enhancement of Skeletal Muscle Mass and Strength by Single Gene Administration of Myostatin Inhibitors." PNAS, 2008. Retrieved 2026-06-15. https://www.pnas.org/doi/10.1073/pnas.0709144105
• Mendell, J.R., et al. "A Phase 1/2a Follistatin Gene Therapy Trial for Becker Muscular Dystrophy." Molecular Therapy, 2015. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/25322757/
• Mendell, J.R., et al. "Follistatin Gene Therapy for Sporadic Inclusion Body Myositis Improves Functional Outcomes." Molecular Therapy, 2017. Retrieved 2026-06-15. https://pmc.ncbi.nlm.nih.gov/articles/PMC5383643/
• "Unfounded Claims of Improved Functional Outcomes Attributed to Follistatin Gene Therapy in Inclusion Body Myositis." Molecular Therapy (commentary), 2017. Retrieved 2026-06-15. https://www.cell.com/molecular-therapy-family/molecular-therapy/fulltext/S1525-0016(17)30414-8
• "The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs." Transgenic Research, 2016. Retrieved 2026-06-15. https://link.springer.com/article/10.1007/s11248-016-9985-x
• Reichel, C., Gmeiner, G., Thevis, M. "Detection of black market follistatin 344." Drug Testing and Analysis, 2019. Retrieved 2026-06-15. https://pubmed.ncbi.nlm.nih.gov/31758732/
• World Anti-Doping Agency. "The Prohibited List." 2026. Retrieved 2026-06-15. https://www.wada-ama.org/en/prohibited-list
• ClinicalTrials.gov. "Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy (NCT01519349)." Retrieved 2026-06-15. https://clinicaltrials.gov/study/NCT01519349